Bristol-Myers Squibb Future Growth
Future criteria checks 2/6
Bristol-Myers Squibb's revenue is forecast to decline at 0.8% per annum while its annual earnings are expected to grow at 8.3% per year. EPS is expected to grow by 14% per annum. Return on equity is forecast to be 64.3% in 3 years.
Key information
8.3%
Earnings growth rate
14.0%
EPS growth rate
Pharmaceuticals earnings growth | 21.0% |
Revenue growth rate | -0.8% |
Future return on equity | 64.3% |
Analyst coverage | Good |
Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Apr 12Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
Apr 02Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 21Bristol-Myers Squibb Is Not A Buy For Me
Mar 19Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Mar 07Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 07We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative
Feb 20Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Feb 06Bristol-Myers Squibb: Massive Discount Spells Opportunity
Feb 04BMY: Might Be Approaching A Bottom In 2024
Jan 23Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings
Jan 16Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
Jan 10Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Dec 31Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60
Dec 26Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now
Dec 19Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock
Dec 12Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60
Dec 11Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08Bristol-Myers Squibb: Time To Get Greedy
Oct 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 44,495 | 10,287 | 13,215 | 14,000 | 20 |
12/31/2025 | 46,342 | 10,309 | 13,990 | 15,189 | 24 |
12/31/2024 | 45,793 | -3,954 | 15,822 | 13,791 | 25 |
12/31/2023 | 45,006 | 8,025 | 12,651 | 13,860 | N/A |
9/30/2023 | 44,935 | 8,285 | 11,468 | 12,914 | N/A |
6/30/2023 | 45,187 | 7,963 | 10,499 | 11,850 | N/A |
3/31/2023 | 45,848 | 7,311 | 10,860 | 12,224 | N/A |
12/31/2022 | 46,159 | 6,327 | 11,948 | 13,066 | N/A |
9/30/2022 | 46,738 | 6,677 | 12,946 | 13,817 | N/A |
6/30/2022 | 47,144 | 6,617 | 14,502 | 15,396 | N/A |
3/31/2022 | 46,960 | 6,251 | 15,347 | 16,195 | N/A |
12/31/2021 | 46,385 | 6,994 | 15,234 | 16,207 | N/A |
9/30/2021 | 45,468 | -5,405 | 14,569 | 15,505 | N/A |
6/30/2021 | 44,384 | -5,079 | 11,687 | 12,506 | N/A |
3/31/2021 | 42,810 | -6,219 | 13,215 | 13,939 | N/A |
12/31/2020 | 42,518 | -9,015 | 13,299 | 14,052 | N/A |
9/30/2020 | 39,395 | -44 | 12,157 | 12,878 | N/A |
6/30/2020 | 34,862 | -563 | 12,409 | 13,167 | N/A |
3/31/2020 | 31,006 | 954 | 9,939 | 10,757 | N/A |
12/31/2019 | 26,145 | 3,439 | 7,374 | 8,210 | N/A |
9/30/2019 | 24,173 | 5,655 | 7,583 | 8,458 | N/A |
6/30/2019 | 23,857 | 6,203 | 6,272 | 7,181 | N/A |
3/31/2019 | 23,288 | 5,144 | 5,239 | 6,155 | N/A |
12/31/2018 | 22,561 | 4,920 | 6,115 | 7,066 | N/A |
9/30/2018 | 22,037 | 1,432 | 3,713 | 4,628 | N/A |
6/30/2018 | 21,600 | 376 | 4,109 | 5,062 | N/A |
3/31/2018 | 21,040 | 919 | 4,586 | 5,589 | N/A |
12/31/2017 | 20,776 | 1,007 | 4,220 | 5,275 | N/A |
9/30/2017 | 20,570 | 4,229 | N/A | 5,601 | N/A |
6/30/2017 | 20,238 | 4,586 | N/A | 5,292 | N/A |
3/31/2017 | 19,965 | 4,836 | N/A | 4,147 | N/A |
12/31/2016 | 19,427 | 4,457 | N/A | 3,058 | N/A |
9/30/2016 | 18,471 | 3,366 | N/A | 2,226 | N/A |
6/30/2016 | 17,618 | 2,870 | N/A | 1,346 | N/A |
3/31/2016 | 16,910 | 1,574 | N/A | 978 | N/A |
12/31/2015 | 16,560 | 1,565 | N/A | 2,105 | N/A |
9/30/2015 | 16,531 | 1,775 | N/A | 1,793 | N/A |
6/30/2015 | 16,383 | 1,790 | N/A | 2,172 | N/A |
3/31/2015 | 16,109 | 2,253 | N/A | 3,157 | N/A |
12/31/2014 | 15,879 | 2,004 | N/A | 3,148 | N/A |
9/30/2014 | 16,062 | 2,717 | N/A | 3,986 | N/A |
6/30/2014 | 16,206 | 2,688 | N/A | 4,136 | N/A |
3/31/2014 | 16,365 | 2,891 | N/A | 4,590 | N/A |
12/31/2013 | 16,385 | 2,563 | N/A | 3,545 | N/A |
9/30/2013 | 16,135 | 2,762 | N/A | 2,971 | N/A |
6/30/2013 | 15,806 | 1,360 | N/A | 6,502 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY's forecast earnings growth (8.3% per year) is above the savings rate (2.3%).
Earnings vs Market: BMY's earnings (8.3% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: BMY's earnings are forecast to grow, but not significantly.
Revenue vs Market: BMY's revenue is expected to decline over the next 3 years (-0.8% per year).
High Growth Revenue: BMY's revenue is forecast to decline over the next 3 years (-0.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be very high in 3 years time (64.3%).